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Abstract: Background: Novel biomarkers and molecular monitoring tools hold potential to improve
outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized
that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRASmut) and CA 19-9
during adjuvant treatment and follow-up might more accurately predict disease course than hitherto
available parameters. Methods: Between 07/2015 and 10/2018, we collected 134 plasma samples from 25
patients after R0/R1-resection of PDAC during adjuvant chemotherapy and post-treatment surveillance
at our institution. Highly sensitive discriminatory multi-target ddPCR assays were employed to screen
plasma samples for cfKRASmut. cfKRASmut and CA 19-9 dynamics were correlated with recurrence-free
survival (RFS) and overall survival (OS). Patients were followed-up until 01/2020. Results: Out of 25
enrolled patients, 76% had undergone R0 resection and 48% of resected PDACs were pN0. 17/25 (68%) of
patients underwent adjuvant chemotherapy. Median follow-up was 22.0 months, with 19 out of 25 (76%)
patients relapsing during study period. Median RFS was 10.0 months, median OS was 22.0 months.
Out of clinicopathologic variables, only postoperative CA 19-9 levels and administration of adjuvant
chemotherapy correlated with survival endpoints. cfKRASmut. was detected in 12/25 (48%) of patients,
and detection of high levels inversely correlated with survival endpoint. Integration of cfKRASmut and
CA 19-9 levels outperformed either individual marker. cfKRASmut outperformed CA 19-9 as dynamic
marker since increase during adjuvant chemotherapy and follow-up was highly predictive of early relapse
and poor OS. Conclusions: Integrated analysis of cfKRASmut and CA 19-9 levels is a promising approach
for molecular monitoring of patients following resection of PDAC. Larger prospective studies are needed
to further develop this approach and dissect each marker’s specific potential. Keywords: Cell-free DNA
(cfDNA); Circulating KRAS (cfKRAS mut); Droplet digital PCR (ddPCR); Liquid biopsy; Molecular
monitoring; Pancreatic cancer; Prognostic biomarkers.
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Abstract
Background: Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients
following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal
analysis of mutated cell-free plasma KRAS (cfKRASmut) and CA 19–9 during adjuvant treatment and follow-up might
more accurately predict disease course than hitherto available parameters.
Methods: Between 07/2015 and 10/2018, we collected 134 plasma samples from 25 patients after R0/R1-resection
of PDAC during adjuvant chemotherapy and post-treatment surveillance at our institution. Highly sensitive
discriminatory multi-target ddPCR assays were employed to screen plasma samples for cfKRASmut. cfKRASmut and CA
19–9 dynamics were correlated with recurrence-free survival (RFS) and overall survival (OS). Patients were followed-
up until 01/2020.
Results: Out of 25 enrolled patients, 76% had undergone R0 resection and 48% of resected PDACs were pN0. 17/
25 (68%) of patients underwent adjuvant chemotherapy. Median follow-up was 22.0 months, with 19 out of 25
(76%) patients relapsing during study period. Median RFS was 10.0 months, median OS was 22.0 months. Out of
clinicopathologic variables, only postoperative CA 19–9 levels and administration of adjuvant chemotherapy
correlated with survival endpoints. cfKRASmut. was detected in 12/25 (48%) of patients, and detection of high levels
inversely correlated with survival endpoint. Integration of cfKRASmut and CA 19–9 levels outperformed either
individual marker. cfKRASmut outperformed CA 19–9 as dynamic marker since increase during adjuvant
chemotherapy and follow-up was highly predictive of early relapse and poor OS.
Conclusions: Integrated analysis of cfKRASmut and CA 19–9 levels is a promising approach for molecular monitoring
of patients following resection of PDAC. Larger prospective studies are needed to further develop this approach
and dissect each marker’s specific potential.
Keywords: Liquid biopsy, Droplet digital PCR (ddPCR), Cell-free DNA (cfDNA), Circulating KRAS (cfKRASmut),
Prognostic biomarkers, Pancreatic cancer, Molecular monitoring
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Background
Despite significant progress in understanding tumor
genetics and the molecular mechanisms driving tumor
development and resistance to therapy, only minor im-
provements have been achieved to date in the treatment
of patients with pancreatic ductal adenocarcinoma
(PDAC). With an average 5-year overall survival (OS)
rate of only 10% across all stages, most patients still suc-
cumb to their disease, making PDAC one of the most
aggressive tumor entities [1–3]. The only potentially
curative treatment is surgical resection of early-stage
tumors [4, 5]. However, recurrence rates even after R0
resection remain unacceptably high [6–10]. The integra-
tion of more efficacious systemic chemotherapy regi-
mens has improved median overall survival [11], yet
responses of individual PDACs to chemotherapy are
highly heterogeneous and personalization of periopera-
tive therapy is in its infancy [12–18] .
Consequently, the development and validation of novel
biomarkers and molecular monitoring tools to predict dis-
ease course and assess efficacy of adjuvant chemotherapy
are urgently needed. The analysis of tumor-derived cell-
free nucleic acids (ctDNA) extracted from the plasma and
other body fluids is a promising tool for molecular diag-
nostics and non-invasive monitoring of cancer patients
[19–26]. Up to 95% of PDACs harbor activating hot spot
mutations in KRAS which are readily detectable in the cir-
culation of PDAC patients [20, 27–29]. We recently de-
scribed the development and validation of highly sensitive
single-target and discriminatory multi-target KRAS
ddPCR assays for the analysis of cfDNA [30]. These assays
allow identification and quantification of mutated KRAS
directly from circulation without previous knowledge of
tumor KRAS mutational status, which is not routinely
tested for resectable PDACs.
For this study, we hypothesized that longitudinal
assessment of cfKRASmut following curative resection of
PDAC in combination with established protein bio-
markers might better identify patients at risk for
imminent tumor relapse, indicate failure of adjuvant
treatment and ultimately guide treatment according to
molecular monitoring. To study the feasibility of this
approach, we analyzed plasma samples collected from
patients undergoing adjuvant chemotherapy and post-
treatment surveillance at our institution in a single-
center retrospective biomarker study aiming to identify
associations between cfKRASmut and CA 19–9 dynamics
and clinical outcome post PDAC resection.
Methods
Study design and population
25 patients with resected pancreatic adenocarcinoma
(following R0 or R1 curative-intended resection) were
included in a retrospective observational single center
biomarker study conducted at Freiburg University Med-
ical Center. Local institutional review board (IRB) ap-
proved all study procedures (EK48/18). All patients
provided written informed consent for sample collection
and analysis. 17/25 patients underwent adjuvant chemo-
therapy (4/17 Gemcitabine, 4/17 FOLFIRINOX, 8/17
Gemcitabine/Capecitabine, 1/17 Gemcitabine/nab-Pacli-
taxel). Further inclusion criteria were “collection of first
sample within 8 weeks after resection”, and “availability
of plasma samples for cfDNA extraction”. Key exclusion
criteria included “R2 resection, evidence of metastatic
disease on pre- or postoperative CT staging, histologies
other than adenocarcinoma”. According to UICC/AJCC,
R0 resection was defined as microscopic edge-negative
resection, in which no microscopic residual tumor
remains. R1 resection was defined as a microscopic re-
sidual tumor and R2 as macroscopically visible residual
tumor. Primary endpoint was detection of cfKRASmut in
at least one sample during study period. Secondary end-
points included association between changes in cfKRAS-
mut and relapse-free survival (RFS) and overall survival
(OS). Additionally, clinical, pathologic, treatment- and
outcome-related data were analyzed.
Collection of patient samples and CA 19–9 analysis
Blood samples were collected at a median of 40 days
(95% CI 26–50) after resection, prior to adjuvant chemo-
therapy and during 3-monthly routine clinical follow-up
visits. CA 19–9 measurements were performed at our
center’s fully certified clinical chemistry facilities. The
threshold value for CA 19–9 positivity was 36 U/ml.
Extraction of cell-free DNA (cfDNA) from plasma samples
Blood samples were collected using commercially avail-
able EDTA tubes and plasma was extracted and frozen
within one hour of collection. Plasma was extracted
through two subsequent centrifugation steps at 3000
rpm and 14,000 rpm, each for 10 min at 4 °C. Obtained
plasma was stored at − 80 °C until extraction of cfDNA.
cfDNA was extracted from 4ml plasma following the
SEP/SBS protocol of the PME-free circulating DNA ex-
traction kit (Analytik Jena, cat. no. 845-IR-0003050), fol-
lowing manufacturer’s instructions. Two subsequent
elution steps with each 30 μl Elution Buffer were per-
formed to optimize the yield of extracted cfDNA. DNA
was stored at − 20 °C until cfDNA quantification. cfDNA
was evaluated with fragment analyzer and quantified
using Qubit 2.0 fluorometer. In patients with resectable
PDAC, DNA yield from 4ml of plasma typically ranged
from 1 to 20 ng/μl.
Droplet digital PCR (ddPCR)
ddPCR for cfKRASmut was performed as recently de-
scribed [29]. Locked nucleic acid (LNA) probes and
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corresponding primer pairs for KRAS mutations were
designed using Beacon Designer v.8.20 software (Premier
Biosoft, Palo Alto, California, USA) and manufactured
by Integrated DNA Technologies (IDT, Inc., Coralville,
Iowa, USA). Wild type (WT) probes were labelled with
hexachlorofluorescein (HEX), mutant (MUT) probes
with 6-carboxyfluorescein (FAM). Primer and Probe se-
quences are listed in Supplemental Table 1. Primers,
probes, template DNA and nuclease-free water (Ambion,
Austin, TX) were added to ddPCR Supermix for Probes
(Bio-Rad, cat. no #186–3024). Reaction mix was set up
as recommended. 20 μl of this reaction mix along with
70 μl reader oil were transferred into cartridges of a
QX100/200TM Droplet Generator (Bio-Rad, cat. no.
#1863002) following manufacturer’s instructions. All
samples were assayed in quadruplicates. Droplets were
generated, transferred into a 96-well PCR plate (Bio-Rad,
cat. no. #12001925) and PCR was then run on a C1000
Touch™ Thermal Cycler (Bio-Rad, cat. no. #1851197). Fi-
nally, samples were analyzed on a QX100/200TM Drop-
let Reader (Bio-Rad, cat. no. 1863003) using QuantaSoft
v1.7.4.0917 (Bio-Rad, cat.no. #1864011). Internal ddPCR
controls were carried out as previously published [29].
The absolute number of copies per milliliter of blood
were calculated as follows: Copies/mL plasma = (copies
per μL of reaction as per QuantaSoft analysis software
version 1.7.4.0917) × (volume of ddPCR reaction) × ([vol-
ume eluted/volume of DNA used in reaction]/volume of
plasma used for cfDNA extraction). Mutant allele fre-
quency was calculated as: Mutant allele frequency = mu-
tant copies/mL of plasma / (mutant copies/mL of
plasma + wild−type copies/mL of plasma).
Limit of detection (LOD) and limit of blank (LOB) of
the individual assays have been previously described [30]
.
In brief, cfDNA was screened for the presence of the
11 most commonly found KRAS hot spot mutations, in
PDAC, covering more than 90% of PDAC cases. Highly
sensitive single-target assays were used to confirm pres-
ence of the mutation identified.
Statistical analysis
Recurrence-free survival (RFS) was defined as time from
resection of PDAC to the first radiologic recurrence
(local or distant) or death due to PDAC. Overall survival
(OS) was defined as time from the date of diagnosis until
death due to any cause. The Kaplan–Meier survival
analysis was performed to calculate both RFS and OS.
Univariate analyses were performed using the log-rank
test. In order to explore independent prognostic factors
for RFS and OS, we used backward stepwise Cox regres-
sion modeling to estimate hazard ratio (HR) with 95%
confidence interval (CI). To compare independent
variables, Chi-squared or Fisher’s exact test and the
Mann–Whitney (rank-sum) test were performed. All
statistical analyses were performed using GraphPad
Prism Version 5.03 (GraphPad Software, Inc., La Jolla,
California, USA) and SPSS 25 software Version
1.0.0.1327 (IBM Corporation, New York, United States).




25 patients with non-metastatic, R0/R1-resected adeno-
carcinoma of the pancreas were included in the study.
Patient characteristics are summarized in Table 1. R0
resection rate was 76% (19/25), 12/25 (48%) of tumors
were nodal negative (pN0). 17/25 (68%) patients under-
went adjuvant chemotherapy. Median follow-up for the
cohort was 22.0 months, with 19 out of 25 (76%) patients
relapsing during this period. Median RFS for the cohort
was 10.0 months, median OS was 22.0 months. We per-
formed univariate and multivariate survival analyses
(Supplemental Tables 2 and 3, Figure S1) for established
clinicopathologic variables. We found no significant cor-
relation between R0 vs R1 resection and RFS or OS (Fig-
ure S1 A, B). However, we identified a significant inverse
correlation between elevated CA 19–9 in the first sample
collected after resection and RFS and OS (Figure S1 C,
D) and significantly better OS (Figure S1 F) but not RFS
(Figure S1 E) for patients undergoing adjuvant
chemotherapy.
Analysis of plasma cfKRASmut
We analyzed 134 plasma samples collected from 25
patients at routine follow-ups before, during and after
adjuvant chemotherapy. First samples were taken at a
median of 40 days (95% CI 26–50) after resection
prior to adjuvant chemotherapy. Median number of
samples collected was 4 samples per patient (95% CI
3–5 samples). Median time interval between sampling
was 70 days (95% CI 63–91). We screened cfDNA ex-
tracted from plasma samples for the presence of
cfKRASmut with recently described discriminatory
multi-target KRAS ddPCR assays, covering the 11
most common KRAS hot spot mutations in PDAC
[30]. At the postoperative stage, no molecular path-
ology data was available for any tumor. However, for
a subset of patients, KRAS mutational status became
available at relapse (Supplemental Table 4).
Across all samples analyzed, cfKRASmut was detected
in 34/134 (25%) samples and 12/25 (48%) of patients for
at least one time point. In 14/15 (93.33%) patients with
later on determined tumor tissue KRAS mutational sta-
tus, the SNV detected by ddPCR in plasma (cfKRASmut)
at any time point matched the KRAS SNV detected in
tissue analysis (Supplemental Table 4), confirming the
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validity of ddPCR cfKRASmut analysis. In 0/134 (0%) of
plasma samples, a concurrent second KRAS SNV could
be detected above assay threshold.
Association of cfKRASmut and elevated CA 19–9 levels
with survival endpoints
Detection of cfKRASmut at any time point during study
course above assay threshold was not associated with
RFS or OS (Fig. 1a, b). However, post-hoc analysis
uncovered that a more stringent cut-off level of 15 cop-
ies KRASmut per ml plasma for cfKRASmut detected at
any time point during study period was strongly associ-
ated with early relapse and poor survival (Fig. 1c, d).
Analogously, when analyzing KRAS variant allele fre-
quencies (VAF) instead of DNA copy numbers, detec-
tion of cfKRASmut above a threshold of 0.5% VAF, as
determined by post hoc analysis, was associated with in-
ferior RFS and OS (Supplemental Figure 2 A, B). Not-
ably, all 5/25 patients with a copy number of 15 copies
KRAS
mut per ml or higher also had a VAF above 0.5%,
while 18/20 patients with a copy number < 15 copies
KRAS
mut per ml had a VAF < 0.5%, suggesting large
overlap between the two distinct ways of analysis. CA
19–9 levels were determined from the same blood col-
lections. 12/25 (48%) of patients had at least one blood
sample with CA 19–9 above normal range during study
course. Increased CA 19–9 at any time point was associ-
ated with significantly inferior RFS and a non-significant
trend towards inferior OS (Fig. 1e, f). Notably, only 6/12
(50%) patients were double positive for cfKRASmut and
CA 19–9, indicating that cfKRASmut and CA 19–9 posi-
tivity are not redundant. Patients with either CA 19–9
positivity or cfKRASmut levels > 15 copies/mL during
study course (14/25, 56%) showed inferior RFS and OS,
indicating that the integration of both biomarkers might
be predictive and prognostic for a larger group of pa-
tients than assaying them individually (Fig. 1g, h). Sur-
vival of double positive patients was similar to single
positive patients in our cohort (data not shown). When
analyzing associations between liquid biomarkers and
clinicopathologic variables, there was no significant cor-
relation between R status and postoperative levels of CA
19–9, cfKRASmut or total cell-free DNA (cfDNA) con-
centrations (Supplemental Figure 2 C, D, E).
Association of cfKRASmut and CA 19–9 dynamics with
survival
Protein tumor markers and cfDNA are highly dynamic
biomarkers for the molecular monitoring of disease
course and treatment response. We therefore next ana-
lyzed whether changes over time in either biomarker are
associated with outcome in our cohort. For each 9/18
(50%) patients with a sufficient number of follow-up
samples, cfKRASmut or CA 19–9 levels increased during
observation period. Increase of cfKRASmut or CA 19–9
during observation period was defined as numerical
increase of the respective parameter in initially positive
patients or rise above threshold in initially negative pa-
tients. Increase of cfKRASmut was associated with signifi-
cantly reduced OS (Fig. 2a), while increase of CA 19–9
was not significantly associated inferior OS (Fig. 2b).
Similarly, early increase of cfKRASmut, defined as in-
crease within 6 months after surgery, was strongly
Table 1 Patient and tumor characteristics
Clinicopathologic features n = 25 (%)
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associated with inferior OS while early CA 19–9 increase
was not significantly associated with shorter OS (Fig. 2c,
d). Integrating both markers for the analysis of dynamic
changes over time did not outperform cfKRASmut alone
(Fig. 2e, f), suggesting that cfKRASmut might be the bio-
marker of choice for longitudinal monitoring in this
setting.
Single patient analysis
Figure 3 illustrates the relationship between cfKRASmut
and CA 19–9 (Fig. 3a) dynamics and tumor relapse for
individual patients. 13/18 patients in the analysis re-
lapsed during observation period. Increase of cfKRASmut
or CA 19–9 was significantly associated with relapse. 09/
13 patients with relapse during observation period
showed an increase in either CA 19–9 or cfKRASmut
(Fig. 3a), 6 out of these 9 patients showed an increase
for both markers indicating partial overlap (not shown).
Notably, 2/5 patients with no relapse during observation
period still showed an increase in either CA 19–9 or
cfKRASmut suggesting either insufficient duration of
follow-up or suboptimal specificity when integrating
Fig. 1 Association of cfKRASmut detection and elevated CA 19–9 levels with survival endpoints. a, b Kaplan-Meier estimates of RFS (a) and OS (b) for
patients following curative resection of PDAC with versus without detectable cfKRASmut at any time point during study period. c, d. A more
stringent cfKRASmut cut-off level of > 15 copies/mL plasma was chosen. e, f Kaplan-Meier estimates of RFS (e) and OS (f) for resected PDAC
patients with elevated (> 36 U/mL) versus normal (≤ 36 U/mL) CA 19–9 levels at any time point during observation period. g, h Kaplan-Meier
estimates of RFS (g) and OS (h) for resected PDAC patients with either CA 19–9 positivity or cfKRASmut levels > 15 copies/mL cfKRAS during study
course. OS, overall survival; RFS, recurrence-free survival; PDAC, pancreatic ductal adenocarcinoma
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both markers for analysis. Single-patient analysis also
illustrates dynamic changes during adjuvant chemother-
apy and follow-up with several patients showing transi-
ent increases followed by decreases of either marker.
Figure 3b illustrates that, in most patients, relapsed was
proceeded by a strong increase of CA 19–9 or cfKRAS-
mut. However, single patient analyses also suggests that
both cfKRASmut and CA 19–9 are highly dynamic bio-
markers and that individual patterns can be highly het-
erogeneous requiring well-defined cut-off levels and
extensive clinical validation for future clinical
application.
Discussion
In an exploratory analysis, we followed a small cohort of
pancreatic cancer patients after curative resection of
pancreatic adenocarcinoma through adjuvant therapy
and post-treatment follow-up. We analyzed mutated
KRAS in cell-free DNA with discriminatory ddPCR as-
says and integrated results with CA 19–9 levels for
Fig. 2 Association of cfKRASmut and CA 19–9 dynamic changes with survival endpoints. a, b Kaplan-Meier estimates of OS for resected PDAC
patients with increase of cfKRASmut (a) or CA 19–9 (b) during observation period. c, d Kaplan-Meier estimates of OS for resected PDAC patients
with early increase of cfKRASmut (a) or CA 19–9 (b) during observation period. Increase of cfKRASmut or CA 19–9 during observation period was
defined as numerical increase of the respective parameter in initially positive patients or rise above threshold in initially negative patients. Early
increase was defined as increase within 6 months after surgery. e Kaplan-Meier estimates of OS for resected PDAC patients with combined early
increase of cfKRASmut or CA 19–9. f Kaplan-Meier estimates of OS for resected PDAC patients with combined early increase of cfKRASmut and CA
19–9. OS, overall survival; RFS, recurrence-free survival; PDAC, pancreatic ductal adenocarcinoma
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association with relapse and survival endpoints. Numer-
ous studies have unveiled the potential of the analysis of
cell-free mutated tumor DNA as novel diagnostic [27],
predictive [31–33] and prognostic [31, 32, 34–37] bio-
marker for pancreatic cancer.
What takes our study apart is the use of discriminatory
multi-target KRAS ddPCR assays [30] to directly identify
KRAS SNVs without performing previous tumor NGS.
These assays have higher sensitivity compared to many
available NGS-based assays [29]. Moreover, the input vol-
ume of 4ml plasma for cfDNA extraction might have
contributed to the comparably higher sensitivity of our as-
says compared to previous reports [26]. In comparison to
more sophisticated NGS panels specifically developed for
cfDNA analysis [29, 38], multi-target ddPCR assays are as-
sociated with much lower assay costs, allowing for the ser-
ial analysis through clinical course analogous to CA 19–9
levels. Using these assays, our cfKRASmut detection rate in
the cohort was similar to other published data for patients
following PDAC resection [20, 31, 36]. A very high con-
cordance rate between tumor tissue und detected cfDNA
KRAS SNVs further validates our approach.
Fig. 3 Longitudinal cfKRASmut and CA 19–9 monitoring. a Top left: Absolut levels of cfKRASmut during observation period. Patients with relapse
during study period are marked red. Black arrow mark the time of disease recurrence. Top right: Relapse versus non-relapse patients with increase
in cfKRASmut during observation period. Fisher’s exact test was used to test for statistical significance between the two groups. P values < 0.05
were considered significant. Bottom left: Absolut levels of CA 19–9 during observation period. Patients with relapse are marked red. Black arrows
mark the time of disease recurrence. Bottom right: Relapse versus non-relapse patients with increase in cfKRASmut during observation period.
Fisher’s exact test was used to test for statistical significance between the two groups. P values < 0.05 were considered significant. b Swimmers
plot of disease course of resected PDAC patients. cfKRASmut and CA 19–9 analysis in blood were compared to clinical course of disease before
and during adjuvant chemotherapy. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease
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In our cohort, detection of cfKRASmut in the first post-
operative sample alone did not significantly correlate
with survival (data not shown), while elevated CA 19–9
levels at first presentation were associated with poor
outcome. Similarly, positivity for cfKRASmut at any time
point above assay threshold alone was not significantly
associated with survival. However, when choosing a
more stringent cfKRASmut cut-off or when analyzing dy-
namic changes (increase vs non-increase), cfKRASmut
was strongly associated with survival and outperformed
CA 19–9 levels for association with relapse and OS,
highlighting the importance of identifying clinically vali-
dated cut-offs for cfDNA analysis [39–41] and also
underlining the limitations associated with analyzing a
small patient cohort.
One main finding of our analysis was that cfKRASmut
positivity and CA 19–9 elevation are only partially over-
lapping and that combining both parameters identifies a
larger cohort of patient with poor outcome. Several
studies have suggested integration of established and ex-
perimental protein biomarkers with cfDNA analysis for
pancreatic cancer early diagnostics [27, 28, 42–44], iden-
tification of minimal residual disease [45] and molecular
monitoring for advanced disease [26, 41]. Our approach
is focused on clinical applicability and feasibility through
integration of the two relatively easy-to-assess bio-
markers cfKRASmut analysis and CA 19–9. Notably, a re-
cent large multi-center case-control study did not find a
benefit if cfKRASmut analysis as compared to CA 19–9
analysis in pancreatic cancer patients across all stages of
disease [26]. In this study, however, reported detection
rates of cfKRASmut were overall lower than in our study,
probably due to differences in assay technology. Our
data suggest that CA 19–9 and cfKRASmut levels each
have their own distinct advantages and disadvantages
and that integrating them for analysis might be superior
to analyzing them individually, the question of how best
to integrate both biomarkers for clinical practice remains
challenging, which is also illustrated by the analysis of
single patient’s disease course in our cohort.
A major limitation of our study is the small cohort
size, which makes it difficult to define clinically relevant
cut-off levels forcfKRASmut and to optimize integration
of CA 19–9 with cfKRASmut. However, despite these lim-
itations, our study also points to the potential of clinic-
ally further developing cfKRASmut as prognostic and
predictive biomarkers for the management of resectable
PDAC. Most importantly, further studies will have to
explore the potential of biomarker-based therapeutic
intervention for pancreatic cancer. Systemic treatment
options for PDAC are limited to a small number of
combination chemotherapy regimens [46, 47] and some
recent developments in personalized treatment based on
molecular profiling [14]. A switch of adjuvant
chemotherapy regimen based on molecular monitoring
appears feasible yet will need extensive clinical validation
in interventional trials, especially since established adju-
vant treatment standards took so many years to
establish.
In summary our study proposed a clinically feasible
approach to assay cfKRASmut together with CA 19–9 in
patients following curative resection of PDAC. Through
combination of both markers, patients could be better
stratified in terms of relapse risk and overall prognosis.
Conclusion
The integrated longitudinal analysis of cfKRASmut and
CA 19–9 levels holds potential for the molecular moni-
toring of patients following resection of PDAC. Larger
cohorts and prospective trials are required to establish
clinically relevant cut-off levels and to better unravel the
relationships between biomarker dynamics and clinical
relapse.
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mut with survival endpoints and clinicopathologic variables. (A, B) Kaplan-
Meier estimates of RFS (A) and OS (B) for patients following curative re-
section of PDAC with versus without cfKRASmut cut-off level of > 0.5%
variant allele frequency (VAF) at any time point during study period. (C,
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treated resected PDAC patients were compared to resection margin. OS,
overall survival; RFS, recurrence-free survival; PDAC, pancreatic ductal
adenocarcinoma
Additional file 2: Table S1. Primer and probe sequences for KRAS
ddPCR assays. Table S2. Overall survival analysis by clinico-pathologic
variables. Table S3. Recurrence-free survival analysis by clinico-
pathologic variables. Table S4. Comparison between tissue analyses and
cfDNA ddPCR.
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